Ajanta Pharma Ltd News

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Ajanta Pharma Q4 FY26 results: Net profit rises 18.4% to ₹266.7 crore

Ajanta Pharma Ltd on Tuesday reported a 18.4 per cent rise in consolidated net profit at Rs 266.7 crore in the fourth quarter ended March 31, on the back of strong US generics revenue growth. The company had posted a consolidated net profit of Rs 225.26 crore in the corresponding period previous fiscal, Ajanta Pharma Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 1,421.64 crore as against Rs 1,170.41 crore in the year-ago period, it added. During the quarter branded generics in the markets of India, Asia and Africa clocked a combined revenue of Rs 859 crore as compared to Rs 805 crore in the year-ago period, up 7 per cent. US generic revenue was at Rs 505 crore as compared to Rs 325 crore in the same period a year ago, up 56 per cent, the company said. Total expenses in the fourth quarter were higher at Rs 1,135.96 crore as compared to Rs 919.11 crore in the same period a year ago, the company said. For FY26, consolidated n

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Stocks with bullish momentum: IDBI Bank, CIL, Graphite, JSL, Ajanta Pharma

Coal India, IDBI Bank, Jindal Stainless, Ajanta Pharma and Graphite India were seen trading above the higher end of the Bollinger Bands backed by strong volume on charts.

Ajanta Pharma shares up 3% as Biocon tie-up fuels long-term growth optimism

Ajanta Pharma shares gained 3% despite a weak market as analysts turned bullish on its Biocon partnership, semaglutide opportunity, and growth outlook

Ajanta Pharma to generate healthy margins from Biocon deal: PL Capital

According to PL Capital, Ajanta Pharma's strong franchise will aid in garnering a higher market share for semaglutide

Stocks with price-volume breakout: Ajanta Pharma, JBMA, Manappuram Finance

Ajanta Pharma, JBMA Auto and Manappuram Finance have seen strong price action backed by heavy trading volume in Wednesday's trading session.

Ajanta Pharma hits over 5-month high after partnering with Biocon

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Ajanta Pharma signs pact with Biocon to sell semaglutide in 26 countries

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Ajanta Pharma sets aside ₹1K crore for acquisitions to plug therapy gaps

Pain management, dermatology, nephrology and gynaecology are emerging as key focus areas

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.